Educational content from recorded physician discussions — not medical advice. Always talk to your child's care team about your child's situation.
Content of this collection
Dose-limiting toxicities at the 11 mg/m2 lenvatinib dose level included proteinuria in one patient and hypertriglyceridemia with hypercholesterolemia in one patient, occurring in 2 of 12 patients treated. A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
Multi-Kinase Inhibitors1 item
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
Read →
Introduction: Developing targeted therapies with manageable toxicities remains a high priority for pediatric cancer. We sought to determine the recommended Phase 2 dose (RP2D) and evaluate the antitumor activity of lenvatinib+everolimus in
article · Nov 2026
BRAF-Targeted Therapy1 item
Pediatric BRAF (V600E)-Mutated Pancreatic Acinar Cell Carcinoma With Complete and Durable Response to Dabrafenib and Trametinib
Read →
JCO precision oncology · 2020
article · Nov 2026
Cytokine release syndrome is a phenomenon of immune hyperactivation described in the setting of cellular and bispecific T-cell engaging immunotherapy. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.
Gamma-Delta T Cell Therapy1 item
In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.
Read →
CD3+ γδ+ T cells comprise 2% to 5% of circulating T cells with Vγ9Vδ2+ cells the dominant circulating subtype. Vγ9Vδ2+ cells recognize non-peptide phosphoantigens and stress-associated NKG2D ligands expressed on malignant cells. Strategies
article · Nov 2026
PD-1 Directed Therapy1 item
Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.
Read →
Cytokine release syndrome (CRS) is a phenomenon of immune hyperactivation described in the setting of cellular and bispecific T-cell engaging immunotherapy. Checkpoint blockade using anti-programmed cell death 1 (anti-PD-1) inhibitors is an
article · Nov 2026
Oncolytic Viral Therapy1 item
Herpes simplex virus oncolytic therapy for pediatric malignancies
Read →
Despite improving survival rates for children with cancer, a subset of patients exist with disease resistant to traditional therapies such as surgery, chemotherapy, and radiation. These patients require newer, targeted treatments used alone
article · Nov 2026
Featured picks for families are being prepared — the summaries above are written for you.
Expert statements from the recordings in this collection.
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
Patients aged 2-21 years with select recurrent or refractory solid tumors were eligible for enrollment.
Phase 2 enrollment was limited to patients with Ewing sarcoma, rhabdomyosarcoma, or high-grade glioma who had received no more than 2 prior VEGF/VEGFR-targeted therapies.
The recommended Phase 2 dose was lenvatinib 11 mg/m2 combined with everolimus 3 mg/m2 orally once daily.
Dose-limiting toxicities at the 11 mg/m2 lenvatinib dose level included proteinuria in one patient and hypertriglyceridemia with hypercholesterolemia in one patient, occurring in 2 of 12 patients treated.
Cites published research
Two patients with rhabdomyosarcoma experienced partial response by Week 16.
Cites published research
Two patients with Ewing sarcoma experienced prolonged disease control lasting at least 23 weeks.
Cites published research
No objective responses were observed in patients with Ewing sarcoma or high-grade glioma by Week 16.
Cites published research
The safety profile in pediatric and young adult patients was similar to that observed in adults with renal cell carcinoma treated with this combination.
Cites published research
Herpes simplex virus oncolytic therapy for pediatric malignancies
A subset of pediatric cancer patients have disease resistant to traditional therapies such as surgery, chemotherapy, and radiation.
Established practice
Patients with treatment-resistant pediatric cancers require newer, targeted treatments used alone or in combination with more traditional approaches.
Oncolytic herpes simplex virus (HSV) offers promise for several difficult to treat pediatric malignancies.
Cites published research
Oncolytic HSV therapy has potential benefit in pediatric solid tumors including brain tumors, neuroblastomas, and sarcomas.
Cites published research
Many challenges need to be addressed prior to moving oncolytic HSV therapy from the laboratory to the bedside in the pediatric population.
Open question
Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.
Cytokine release syndrome is a phenomenon of immune hyperactivation described in the setting of cellular and bispecific T-cell engaging immunotherapy.
Established practice
Severe cytokine release syndrome can occur in patients receiving anti-PD-1 checkpoint blockade therapy.
Cites published research
In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.
CD3+ γδ+ T cells comprise 2% to 5% of circulating T cells with Vγ9Vδ2+ cells the dominant circulating subtype.
Established practice
Vγ9Vδ2+ cells recognize non-peptide phosphoantigens and stress-associated NKG2D ligands expressed on malignant cells.
Established practice
